Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    ...
    9
    ...
ATC Name B/G Ingredients Dosage Form Price
C09CA04 ZIOREL G Irbesartan - 300mg 300mg Tablet, film coated 575,933 L.L
C10AA07 ROVASTIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 618,168 L.L
D10AF01 MEDACIN T G Clindamycin (phosphate) - 10mg/ml 10mg/ml Solution 314,459 L.L
G04CA02 MINGO G Tamsulosin - 0.4mg 0.4mg Capsule 673,201 L.L
J01DD02 CEFTAZIDIME PANPHARMA G Ceftazidime (pentahydrate) - 1g 1g Injectable powder for solution 3,300,477 L.L
J01RA SPIRAGYL G Metronidazole - 125mg, Spiramycin - 750,000IU Tablet, scored 474,824 L.L
L01AX03 TEMOZOLOMIDE GP PHARM G Temozolomide - 5mg 5mg Capsule, hard 1,153,017 L.L
M02AA15 OLFEN G Diclofenac sodium (diethylamine) - 1% 1% Gel 268,769 L.L
N05AH03 OLIZAX 10 G Olanzapine - 10mg 10mg Tablet, mouth dissolving 2,598,096 L.L
R03DA11 ANSIMAR G Doxofylline - 400mg 400mg Tablet 544,256 L.L
A02BC01 AXIPRON G Omeprazole - 20mg 20mg Capsule 373,358 L.L
A07EA02 HEMORRANE G Hydrocortisone acetate - 10mg/g 10mg/g Ointment 710,893 L.L
B05CX01 DEXTROSE 5% INJECTION, USP G Glucose - 5% 5% Injectable solution 158,587 L.L
C05AA01 SEDIPROCT G Hydrocortisone - 5mg, Cinchocaine HCl - 5mg, Framycetin sulfate - 10mg, Esculoside - 10mg Suppository 237,860 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 720,525 L.L
D10AF01 CLINIDERM G Clindamycin (phosphate) - 1% 1% Gel 712,876 L.L
G04CA02 PROSTAFINE G Tamsulosin HCl - 0.4mg 0.4mg Capsule, modified release 761,511 L.L
J01DD02 FORTECARE G Ceftazidime - 1g 1g Injectable powder for solution 10,011,695 L.L
J01RA SPIRAGYL FORTE G Metronidazole - 250mg, Spiramycin - 1,500,000IU Tablet, scored 474,824 L.L
L01AX04 DACARBAZINE MEDAC G Dacarbazine - 200mg 200mg Injectable powder for solution 15,866,076 L.L
M02AA15 VOLDIC G Diclofenac sodium (diethylamine) - 10mg/g 1% Emulgel 172,012 L.L
N02BE01 PARACEROL G Paracetamol - 10mg/ml 10mg/ml Injectable solution 1,536,012 L.L
N05AH03 PRANZA G Olanzapine - 10mg 10mg Tablet, orodispersible 3,553,120 L.L
N06CA02 MELIXITE G Flupentixol (dihydrochloride) - 0.5mg, Melitracen (HCl) - 10mg Tablet, film coated 600,250 L.L
R03DA55 CAMPHO-PNEUMINE AMINOPHYLLINE ENFANTS G Eucalyptol - 0.03g, Camphre - 0.04g, Gaiacol ethyl glycolate - 0.12g, Aminophylline - 0.06g Suppository 284,127 L.L
S01ED51 DORZOLAMIDE/TIMOLOL BGR G Timolol maleate - 5mg/ml, Dorzolamide HCl - 20mg/ml Drops solution 689,391 L.L
A02BC01 DIGCAP G Omeprazole - 20mg 20mg Capsule 593,850 L.L
A10BK03 EMPAZA G Empagliflozin - 25mg 25mg Tablet, film coated 1,740,724 L.L
B05CX01 DEXTROSE INJECTION 5% G Dextrose, H2O - 5g/100ml Injectable solution 212,797 L.L
C05AA01 SINAHEAL-H G Hydrocortisone acetate - 5mg, Lidocaine - 60mg, Zinc oxide - 400mg, Aluminium Subacetate - 50mg Suppository 501,253 L.L
    ...
    9
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025